Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Killick, Emma ^a   Morgan, Richard ^c   Launchbury, Francesca ^c   Bancroft, Elizabeth ^b   Page, Elizabeth ^a   Castro, Elena ^a   Kote Jarai, Zsofia ^a   Aprikian, Armen ^d   Blanco, Ignacio ^e   Clowes, Virginia ^f   Domchek, Susan ^g   Douglas, Fiona ^h   Eccles, Diana ⁱ   Evans, D Gareth ^j   Harris, Marion ^k   Kirk, Judy ^l   Lam, Jimmy ^m   Lindeman, Geoffrey ⁿ   Mitchell, Gillian ^o,p   Pachter, Nicholas ^q   Selkirk, Christina ^r   Tucker, Kathy ^s   Zgajnar, Janaz ^t   Eeles, Rosalind ^a,b   Pandha, Hardev ^c   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h Institute of Human Genetics   (United Kingdom)

ⁱ Wessex Clinical Genetics Service   (United Kingdom)

^j MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^k MONASH MEDICAL CENTRE   (Australia)

^l WESTMEAD HOSPITAL   (Australia)

^m REPATRIATION GENERAL HOSPITAL   (Australia)

ⁿ ROYAL MELBOURNE HOSPITAL   (Australia)

^o PETER MACCALLUM CANCER CENTRE   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

^q KING EDWARD MEMORIAL HOSPITAL   (Australia)

^r NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^s PRINCE OF WALES HOSPITAL   (Australia)

^t INSTITUTE OF ONCOLOGY   (Slovenia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENGRAILED 2 PROTEIN; HOMEODOMAIN PROTEIN; NERVE PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; BLOOD; GENETICS; HUMAN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR GENE; URINE; ARTICLE; PROSTATE TUMOR;

ADULT; AGED; GENES, BRCA1; GENES, BRCA2; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889565733     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02059     Document Type: Article

References (24)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 62, 10-29 (2012).
2. South West Public Health Observatory. SWPHO Briefing: Prostate cancer survival by stage, (2008). Date accessed 15.07.11.
3. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360, 1310-1319 (2009).
4. Schroder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 1320-1328 (2009).
5. Goh, C. L. et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 271, 353-365 (2012).
6. Kote-Jarai, Z. et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105, 1230-1234 (2011).
7. Leongamornlert, D. et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106, 1697-1701 (2012).
8. Fachal, L. et al. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. Prostate 71, 1768-1779 (2011).
9. Mitra, A. V. et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 107, 28-39 (2011).
10. Martin, N. L., Saba-El-Leil, M. K., Sadekova, S., Meloche, S. & Sauvageau, G. EN2 is a candidate oncogene in human breast cancer. Oncogene 24, 6890-6901 (2005).
11. Morgan, R. et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 17, 1090-1098 (2011).
12. Pandha, H. et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int 110, E287-292 (2012).
13. NICE. Prostate cancer: Diagnosis and treatment, (2008). Date accessed 28.06.12.
14. Mitra, A. et al. Prostate cancer inmale BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98, 502-507 (2008).
15. USPSTF. Screening for prostate cancer: draft recommendation statement. Rockville, MD: U.S. Preventive Services Task Force, (2011). Date accessed 13.03.13.
16. Pandha, H. et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int (2012).
17. Epstein, J. I. et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160, 2407-2411 (1998).
18. Norberg, M. et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50, 562-566 (1997).
19. Pal, R. P., Elmussareh, M., Chanawani, M. & Khan, M. A. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int 109, 367-371 (2012).
20. Thompson, I. M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350, 2239-2246 (2004).
21. Canby-Hagino, E. et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 70, 748-752 (2007).
22. Thompson, I. M. et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294, 66-70 (2005).
23. Shah, R. B. Current perspectives on the Gleason grading of prostate cancer. Arch Pathol Lab Med 133, 1810-1816 (2009).
24. Gleason, D. F. & Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111, 58-64 (1974).